Article

(2021) Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. p. 172. ISSN 1537-6591 (Electronic) 1058-4838 (Linking)

(2021) Erratum: SD1000: High Sustained Viral Response Rate in 1361 Patients with Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial (Clin Infect Dis (2020) 70:10 (2206-2212) DOI: 10.1093/cid/ciz628). Clinical Infectious Diseases. p. 172. ISSN 10584838 (ISSN)

(2021) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial (vol 70, pg 2206, 2020). Clinical Infectious Diseases. p. 172. ISSN 1058-4838

(2020) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases. pp. 2206-2212. ISSN 1058-4838

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2017) Assessing the Sleep Quality and Depression-Anxiety-Stress in Irritable Bowel Syndrome Patients. Arquivos de gastroenterologia. pp. 163-166. ISSN 1678-4219 (Electronic) 0004-2803 (Linking)

(2016) Serum immune biomarkers in irritable bowel syndrome. Clinics and Research in Hepatology and Gastroenterology. pp. 631-637. ISSN 2210-7401

(2015) Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepatitis Monthly. p. 6. ISSN 1735-143X

(2015) Increasing Trend in Colorectal Cancer Incidence in the Southeast of Iran 2003-2013: A Population Based Cancer Registry Study. Asian Pacific journal of cancer prevention : APJCP. pp. 5257-60. ISSN 2476-762X (Electronic) 1513-7368 (Linking)